Security Snapshot

Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) Institutional Ownership

CUSIP: 114082308

13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

19

Shares (Excl. Options)

3,574,358

Price

$0.20

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+3,035,631
Value change
+$590,836
Number of holders
19
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
1,216,283
SEC-reported price per share
$0.20
Insider filing price
$0.20
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share is tracked under CUSIP 114082308.
  • 19 institutions reported positions in Q1 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 14 to 19 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $627,089 to $711,400.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 19 institutions filings for Q1 2026.

Open SEC evidence

Security key

114082308

Latest holder period

Q1 2026

13F holders

19

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
ERNA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Cherington Charles 35% $12,949,602 10,791,335 Charles Cherington 10 Feb 2026
Konar Shameek 7.1% $720,505 558,531 Shameek Konar 30 Jun 2025
IAF, LLC 4.1% $584,191 315,779 IAF, LLC 28 Jul 2025
Freebird Partners LP 9.9% 0% $24,082 -$133,126 120,412 -85% Freebird Partners LP 10 Feb 2026
HALPERN JOHN D 5.6% $13,350 66,751 John D. Halpern 10 Feb 2026

As of 31 Mar 2026, 19 institutional investors reported holding 3,574,358 shares of Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA). This represents 294% of the company’s total 1,216,283 outstanding shares.

13F concentration

Top 23 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
294%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Bleichroeder LP 164% 2,000,000 0.07% $398,000
Dauntless Investment Group, LLC 50% 612,443 0.34% $121,876
Corient Private Wealth LLC 36% 438,093 +0% 0% $87,181
GEODE CAPITAL MANAGEMENT, LLC 20% 244,446 +935% 0% $48,643
XTX Topco Ltd 4.5% 54,338 0% $10,813
Warberg Asset Management LLC 4.1% 50,000 0% $10,055
JANE STREET GROUP, LLC 3.4% 41,167 0% $8,192
CITADEL ADVISORS LLC 2.7% 33,076 0% $6,582
VANGUARD CAPITAL MANAGEMENT LLC 2.2% 26,504 0% 0% $5,274
VANGUARD FIDUCIARY TRUST CO 2.1% 25,447 0% 0% $5,064
UBS Group AG 1.7% 21,233 +3439% 0% $4,225
GOLDMAN SACHS GROUP INC 1.4% 16,631 0% $3,310
Sippican Capital Advisors 0.82% 10,000 0% 0% $1,990
BlackRock, Inc. 0.07% 820 0% 0% $163
ASSETMARK, INC 0.01% 133 0% 0% $26
BNP PARIBAS FINANCIAL MARKETS 0% 10 0% 0% $2
MONTAG A & ASSOCIATES INC 0% 8 0% 0% $2
SBI Securities Co., Ltd. 0% 6 0% $1
Activest Wealth Management 0% 3 0% 0% $1
Fortitude Family Office, LLC 0% 0 -100% $0
HRT FINANCIAL LP 0% 0 -100% $0
BANK OF AMERICA CORP /DE/ 0% 0 -100% $0
MORGAN STANLEY 0% 0 -100% $0

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
4
Latest
Q1 2026
Rows shown
1-4 of 4
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 3,574,358 $711,400 +$590,836 $0.20 19
2025 Q4 522,698 $627,089 +$10,571 $1.20 14
2025 Q3 516,928 $566,036 +$511,087 $1.10 14
2025 Q2 49,811 $91,652 +$91,634 $1.84 12
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .